logo
Share SHARE
FONT-SIZE Plus   Neg

Covanta Holding Slips To Loss In Q1; Backs FY12 Adj. EPS View - Quick Facts

Covanta Holding Corp. (CVA) reported that its first-quarter net loss attributable to the company was $12 million or $0.09 per share, compared to net income of $133 million or $0.91 per share in the same quarter last year.

Loss from continuing operations narrowed to $11 million from $14 million in the year ago quarter.

Adjusted loss narrowed to $0.09 per share from $0.10 per share in the year ago quarter. Analysts polled by Thomson Reuters expected the company to report a loss of $0.08 per share for the quarter. Analysts' estimates typically exclude special items.

Total operating revenues grew 4%, to $392 million, from $377 million prior year. Seven analysts had consensus revenue estimate of $ 386.54 million for the quarter. The increase was primarily attributed to higher construction revenues, increased revenue from service fee contract escalations and increased recycled metal revenues due to organic growth initiatives which increased volume as well as higher pricing from improved quality.

The company still expects 2012 adjusted earnings per share in the range of $0.55-$0.65. Analysts expect the company to report earnings of $0.60 per share for fiscal 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Monday reported strong U.S. vehicle sales for the month of July, driven by continued demand for trucks and sport-utility vehicles amid an improving economy, lower gas prices and easy availability of credit. Detroit's Big Three - General Motors Co., Ford Motor Co. and FCA US, LLC - all reported vehicle sales above analyst expectations. British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates.
comments powered by Disqus
RELATED NEWS
Trade CVA now with 
Follow RTT